A Network Meta-Analysis on Randomized Trials Focusing on the Preventive Effect of Statins on Contrast-Induced Nephropathy

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Peruzzi, Mariangela ^a   De Luca, Leonardo ^b   Thomsen, Henrik S ^c   Romagnoli, Enrico ^d   D'Ascenzo, Fabrizio ^e   Mancone, Massimo ^a   Sardella, Gennaro ^a   Lucisano, Luigi ^a   Abbate, Antonio ^f   Frati, Giacomo ^a,g   Biondi Zoccai, Giuseppe ^a,f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b EUROPEAN HOSPITAL   (Italy)

^c Mental Health Services CPH   (Denmark)

^d Institute of Cardiology   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATININE; IOBITRIDOL; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; PLACEBO; ROSUVASTATIN; SIMVASTATIN; CONTRAST MEDIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGIOCARDIOGRAPHY; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFECT; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; HUMAN; LOW DRUG DOSE; META ANALYSIS; PREVALENCE; REVIEW; RISK REDUCTION; CHEMICALLY INDUCED; CONFIDENCE INTERVAL; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; RISK; RISK FACTOR;

CONFIDENCE INTERVALS; CONTRAST MEDIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84921879735     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/213239     Document Type: Review

References (30)

1. J. Golshahi, H. Nasri, and M. Gharipour, "Contrast-induced nephropathy; A literature review, " Journal of Nephropathology, vol. 3, no. 2, pp. 51-56, 2014.
2. T. Senoo, M. Motohiro, H. Kamihata et al., "Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome, "TheAmerican Journal of Cardiology, vol. 105, no. 5, pp. 624-628, 2010.
3. J. Wi, Y. G. Ko, J. S. Kim et al., "Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention, " Heart, vol. 97, no. 21, pp. 1753-1757, 2011.
4. Y. Han, G. Zhu, L. Han et al., "Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease, " Journal of the American College of Cardiology, vol. 63, no. 1, pp. 62-70, 2013.
5. S. N. Heyman, J. Reichman, and M. Brezis, "Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia, " Investigative Radiology, vol. 34, no. 11, pp. 685-691, 1999.
6. J. A. Farmer, "Pleiotropic effects of statins, " Current Atherosclerosis Reports, vol. 2, no. 3, pp. 208-217, 2000.
7. M. H. Shishehbor, R. J. Aviles, M. Brennan et al., "Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy, " The Journal of the American Medical Association, vol. 289, no. 13, pp. 1675-1680, 2003.
8. S. Cao, P. Wang, K. Cui, L. Zhang, and Y. Hou, "Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress, " Nan Fang Yi Ke Da Xue Xue Bao, vol. 32, no. 11, pp. 1600-1602, 2012.
9. S. Jo, B. Koo, J. Park et al., "Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study, " American Heart Journal, vol. 155, no. 3, pp. 499-e1-499-e8, 2008.
10. S. H. Jo, J. Y. Hahn, S. Y. Lee et al., "High-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention, " Journal of Cardiovascular Medicine (Hagerstown), 2014.
11. A. Kaya, M. Kurt, I. H. Tanboga et al., "Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial), " Acta Cardiologica, vol. 68, no. 5, pp. 489-494, 2013.
12. M. Leoncini, A. Toso, M. Maioli, F. Tropeano, S. Villani, and F. Bellandi, "Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome), " Journal of the American College of Cardiology, vol. 63, no. 1, pp. 71-79, 2014.
13. W. Li, X. Fu, Y. Wang et al., "Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention, " Cardiology, vol. 122, no. 3, pp. 195-202, 2012.
14. H. Li, X. Li, H. Ma et al., "Atorvastatin combiningwith probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure, " Scientific World Journal, vol. 2014, Article ID 565367, 6 pages, 2014.
15. H. Ozhan, I. Erden, S. Ordu et al., "Efficacy of short-term highdose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography, " Angiology, vol. 61, no. 7, pp. 711-714, 2010.
16. G. Patti, E. Ricottini, A. Nusca et al., "Short-term, highdose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN atorvastatin for reduction ofmyocardial damage during angioplasty-contrast-induced nephropathy trial, " American Journal of Cardiology, vol. 108, no. 1, pp. 1-7, 2011.
17. C. Quintavalle, D. Fiore, F. de Micco et al., "Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury, " Circulation, vol. 126, no. 25, pp. 3008-3016, 2012.
18. A. Toso, M. Maioli, M. Leoncini et al., "Usefulness of Atorvastatin (80mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease, " The American Journal of Cardiology, vol. 105, no. 3, pp. 288-292, 2010.
19. J. Xinwei, F. Xianghua, Z. Jing et al., "Comparison of usefulness of simvastatin 20mg versus 80mg in preventing contrastinduced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention, " The American Journal of Cardiology, vol. 104, no. 4, pp. 519-524, 2009.
20. X. Zhou, Y. Jin, Q. Wang, R. Min, andX. Zhang, "Efficacyofhigh dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography, " Zhonghua Xin Xue Guan Bing Za Zhi, vol. 37, no. 5, pp. 394-396, 2009.
21. T. Greco, G. Landoni, G. Biondi-Zoccai et al., "A Bayesian network meta-analysis for binary outcome: how to do it, " Statistical Methods in Medical Research, 2013.
22. F. DAscenzo and G. Biondi-Zoccai, "Network meta-analyses: the "White Whale" for cardiovascular specialists, " Journal of Cardiothoracic and Vascular Anesthesia, vol. 28, no. 1, pp. 169-173, 2013.
23. G. Biondi-Zoccai, Network Meta-Analysis: Evidence Synthesis with Mixed Treatment Comparison, Nova Science Publishers, Hauppauge, NY, USA, 2014.
24. G. G. L. Biondi-Zoccai, P. Agostoni, A. Abbate, L. Testa, F. Burzotta, and K. A. Robinson, "A simple hint to improve Robinson and Dickersins highly sensitive PubMed search strategy for controlled clinical trials, " International Journal of Epidemiology, vol. 34, no. 1, pp. 224-225, 2005.
25. G. Biondi-Zoccai, M. Lotrionte, H. S. Thomsen et al., "Nephropathy after administration of iso-osmolar and lowosmolar contrast media: evidence from a network metaanalysis, " International Journal of Cardiology, vol. 172, no. 2, pp. 375-80, 2014.
26. C. Haller and I. Hizoh, "The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro, " Investigative Radiology, vol. 39, no. 3, pp. 149-154, 2004.
27. A. Pisani, M. Sabbatini, E. Riccio et al., "Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury, " Clinical and Experimental Nephrology, vol. 181, no. 3, pp. 424-431, 2013.
28. J. G. Webb, G. E. Pate, K. H. Humphries et al., "A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect, " American Heart Journal, vol. 148, no. 3, pp. 422-429, 2004.
29. S. Khanal, N. Attallah, D. E. Smith et al., "Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions, " American Journal ofMedicine, vol. 118, no. 8, pp. 843-849, 2005.
30. R. E. Katholi, W. T. Woods Jr., G. J. Taylor et al., "Oxygen free radicals and contrast nephropathy, " American Journal of Kidney Diseases, vol. 32, no. 1, pp. 64-71, 1998.